Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

Imaging host-Leishmania interactions: significance in visceral leishmaniasis.

Forestier CL.

Parasite Immunol. 2013 Sep-Oct;35(9-10):256-66. doi: 10.1111/pim.12044. Review.

2.

Determinants for the development of visceral leishmaniasis disease.

McCall LI, Zhang WW, Matlashewski G.

PLoS Pathog. 2013 Jan;9(1):e1003053. doi: 10.1371/journal.ppat.1003053. Epub 2013 Jan 3. Review.

3.

Immunopathogenesis of infection with the visceralizing Leishmania species.

Wilson ME, Jeronimo SM, Pearson RD.

Microb Pathog. 2005 Apr;38(4):147-60. Review.

PMID:
15797810
4.

Immunopathogenesis of non-healing American cutaneous leishmaniasis and progressive visceral leishmaniasis.

Soong L, Henard CA, Melby PC.

Semin Immunopathol. 2012 Nov;34(6):735-51. doi: 10.1007/s00281-012-0350-8. Epub 2012 Oct 11. Review.

5.

In vivo imaging of transgenic Leishmania parasites in a live host.

Thalhofer CJ, Graff JW, Love-Homan L, Hickerson SM, Craft N, Beverley SM, Wilson ME.

J Vis Exp. 2010 Jul 27;(41). pii: 1980. doi: 10.3791/1980.

6.

Permissive and protective roles for neutrophils in leishmaniasis.

Carlsen ED, Liang Y, Shelite TR, Walker DH, Melby PC, Soong L.

Clin Exp Immunol. 2015 Nov;182(2):109-18. doi: 10.1111/cei.12674. Epub 2015 Aug 28. Review.

PMID:
26126690
7.

Chemokines in host-parasite interactions in leishmaniasis.

Teixeira MJ, Teixeira CR, Andrade BB, Barral-Netto M, Barral A.

Trends Parasitol. 2006 Jan;22(1):32-40. Epub 2005 Nov 23. Review.

PMID:
16310413
8.

Visceral leishmaniasis: host-parasite interactions and clinical presentation in the immunocompetent and in the immunocompromised host.

Saporito L, Giammanco GM, De Grazia S, Colomba C.

Int J Infect Dis. 2013 Aug;17(8):e572-6. doi: 10.1016/j.ijid.2012.12.024. Epub 2013 Feb 4. Review.

9.

A novel mechanism for an old drug: amphotericin B in the treatment of visceral leishmaniasis.

Chattopadhyay A, Jafurulla M.

Biochem Biophys Res Commun. 2011 Dec 9;416(1-2):7-12. doi: 10.1016/j.bbrc.2011.11.023. Epub 2011 Nov 10. Review.

PMID:
22100811
10.

Immunomodulation by chemotherapeutic agents against Leishmaniasis.

Saha P, Mukhopadhyay D, Chatterjee M.

Int Immunopharmacol. 2011 Nov;11(11):1668-79. doi: 10.1016/j.intimp.2011.08.002. Epub 2011 Aug 27. Review.

PMID:
21875692
11.

Lingual leishmaniasis complicating visceral disease.

Mazumder SA, Pandey S, Brewer SC, Baselski VS, Weina PJ, Land MA, Fleckenstein JM.

J Travel Med. 2010 May-Jun;17(3):212-4. doi: 10.1111/j.1708-8305.2010.00403.x.

12.

[Immunopathogenesis of Leishmania infections].

Yurdakul P.

Mikrobiyol Bul. 2005 Jul;39(3):363-81. Review. Turkish.

PMID:
16358498
13.

Macrophages, pathology and parasite persistence in experimental visceral leishmaniasis.

Engwerda CR, Ato M, Kaye PM.

Trends Parasitol. 2004 Nov;20(11):524-30. Review.

PMID:
15471704
14.

Therapeutic options for visceral leishmaniasis.

Monge-Maillo B, López-Vélez R.

Drugs. 2013 Nov;73(17):1863-88. doi: 10.1007/s40265-013-0133-0. Review.

15.

Interaction of Leishmania with the host macrophage.

Handman E, Bullen DV.

Trends Parasitol. 2002 Aug;18(8):332-4. Review.

PMID:
12377273
16.
17.

Vaccine candidates for leishmaniasis: a review.

Nagill R, Kaur S.

Int Immunopharmacol. 2011 Oct;11(10):1464-88. doi: 10.1016/j.intimp.2011.05.008. Epub 2011 May 25. Review.

PMID:
21616175
18.

Imaging of the host/parasite interplay in cutaneous leishmaniasis.

Millington OR, Myburgh E, Mottram JC, Alexander J.

Exp Parasitol. 2010 Nov;126(3):310-7. doi: 10.1016/j.exppara.2010.05.014. Epub 2010 May 23. Review.

19.

Transgenic Leishmania and the immune response to infection.

Beattie L, Evans KJ, Kaye PM, Smith DF.

Parasite Immunol. 2008 Apr;30(4):255-66. doi: 10.1111/j.1365-3024.2008.01020.x. Epub 2008 Feb 4. Review.

20.

Leishmaniasis: recognition and management with a focus on the immunocompromised patient.

Choi CM, Lerner EA.

Am J Clin Dermatol. 2002;3(2):91-105. Review.

PMID:
11893221
Items per page

Supplemental Content

Write to the Help Desk